Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis

Mohammad H Derakhshan, Linda Dean, Gareth T Jones, Stefan Siebert, Karl Gaffney

ABSTRACT

Objectives Extra-articular manifestations (EAMs) are important systemic features of axial spondyloarthritis (axSpA), which may influence the choice of tumour necrosis factor-inhibitor (TNFi). We examined the cumulative incidence and predictors of EAMs and the influence of these on first TNFi choice in a 'real-world' cohort of patients with axSpA.

Methods Clinical and patient-reported outcomes of 2420 patients with axSpA from 83 centres were collected by the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis. Lifestyle factors for EAMs (acute anterior uveitis (AAU), inflammatory bowel diseases (IBD), psoriasis) were compared with those without EAMs. Also, the association between pretreatment EAMs and choice of first TNFi (adalimumab, etanercept, certolizumab) was analysed.

Results AAU was directly associated with human leukocyte antigen (HLA)-B27 (incidence rate ratio (IRR) 1.95, 95% CI 1.40 to 2.73) and inversely associated with ever-smoking (IRR=0.71, 95% CI 0.55 to 0.92). For both psoriasis and IBD, there was an inverse relationship with HLA-B27 (IRR 0.54, 95% CI 0.36 to 0.79 and IRR 0.63, 95% CI 0.43 to 0.91, respectively). A diagnosis of either AAU (OR 3.79, 95% CI 2.11 to 6.80) or IBD (OR 5.50, 95% CI 2.09 to 14.46) was associated with preference for adalimumab, etanercept, certolizumab) was analysed.

Conclusion The higher occurrence of AAU and lower occurrence of psoriasis and IBD in HLA-B27-positive patients with axSpA are consistent with current pathophysiology. Patients with previous AAU and IBD are more likely to be prescribed adalimumab and less likely to receive etanercept, consistent with the superior efficacy of monoclonal TNFi for these indications. Future work will determine whether EAMs influence TNFi survival, or effectiveness, and whether this varies between agents.

INTRODUCTION

Extra-articular manifestations (EAMs) are common and important systemic features of axial spondyloarthritis (axSpA), the most common being acute anterior uveitis (AAU), inflammatory bowel disease (IBD) and psoriasis. It has...
previously been estimated that the pooled prevalence of AAU, psoriasis and IBD in axSpA are 16–23%, 10–11% and 4–6%, respectively. The prevalence of EAMs is broadly similar in ankylosing spondylitis (AS; also called radiographic axSpA) and non-radiographic axSpA (nr-axSpA), except for AAU prevalence that is higher in AS than nr-axSpA. EAMs contribute to the disease burden and add a layer of complexity to the management of axSpA.

National and international recommendations for the management of axSpA consistently highlight the importance of considering EAMs when choosing the appropriate tumour necrosis factor inhibitor (TNFi) due to their different modes of action and efficacy in the context of individual EAMs. In the UK, Europe and North America, five originator TNFi are currently licensed to treat axSpA; adalimumab, certolizumab pegol, etanercept, golimumab and infliximab (AS only). Several TNFi are also licensed to treat psoriasis (all except golimumab) and IBD (ulcerative colitis—adalimumab, certolizumab pegol, etanercept, golimumab and infliximab; Crohn’s disease—adalimumab and infliximab (certolizumab in the USA and Switzerland only)). However, no TNFi are currently licensed to treat AAU in adults, although adalimumab is licensed to treat non-infectious intermediate, posterior and panuveitis.

In a post-hoc analysis of randomised controlled trials for axSpA and other conditions, as well as in many observational studies, it has been shown that monoclonal TNFi are efficacious in AAU, with monoclonal antibody TNFi showing superior efficacy over etanercept. EAMs therefore have important implications for the use of TNFi, particularly the soluble fusion protein etanercept, in the management of axSpA. However, it is not feasible or ethical to randomise patients with axSpA and specific EAMs to specific treatments in conventional randomised controlled trial settings, so data from real-world cohorts are required. Specifically, physicians’ beliefs and knowledge about the efficacy and safety of specific TNFi for AAU, IBD and psoriasis are likely to influence their choice of TNFi in patients with axSpA. The purpose of this study is to examine the cumulative incidence and predictors for developing EAMs and their influence on physicians’ prescribing patterns for the first TNFi in a ‘real-life’ cohort of patients with axSpA recruited in the UK.

METHODS
Participants data
The British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS) is a UK-wide prospective observational cohort study of patients with axSpA recruited from 83 centres and fulfilling the Assessment of SpondyloArthritis International Society (ASAS) classification criteria. The BSRBR-AS study protocol has been published previously. Baseline data were obtained between December 2012 and June 2017 using a combination of a targeted medical history, participant self-completed questionnaires and the participants’ medical records. The presence or absence of EAMs (ever diagnosis), defined as physician-verified diagnosis of AAU, psoriasis and IBD, were specifically recorded prior to commencing biological therapy. Demographic data included age, disease duration (time between symptom onset to BSRBRAS baseline visit), body mass index (BMI), cigarette smoking status (ever vs never used for this analysis), alcohol consumption and educational status. Human leukocyte antigen (HLA)-B27 status was determined from either medical records or analysis of patients’ saliva samples.

In the original data set, there were only a small proportion of missing data (≤5%) in variables of interests; therefore, we have not applied any imputation methods to our data set.

Ethical approval was obtained from the National Research Ethics Service Committee North East—County Durham and Tees Valley (reference 11/NE/0374), and signed informed consent was obtained from all participants.

Statistical analysis
Descriptive statistics were used to compare participant characteristics according to presence or absence (ever diagnosis) of AAU, psoriasis and IBD (either Crohn’s disease or ulcerative colitis), with central tendencies in groups presented as median and IQR, unless otherwise stated. Where necessary, the difference between independent groups was examined using the Mann–Whitney U test. Poisson log-linear models were used to examine the associations between each EAM (AAU, psoriasis, IBD) and demographic, lifestyle and HLA-B27 status. In unadjusted models, estimates of incidence rate ratio (IRR) and relevant 95% CI were calculated with one EAM as response and one factor as predictor. In adjusted models, all factors (categorical) and covariate (continuous) variables showing significant association (p<0.05) with the response in univariable analysis were entered in the model. In final models, when AAU was the response, HLA-B27 (reference: negative), university degree (reference: no) and ever-smoking (reference: never) were factors, and age (years) and axSpA disease duration (years) were covariates. In the model for psoriasis, HLA-B27 (reference: negative), university degree (reference: no) and ever-smoking (reference: never) were factors, and age (years) and BMI were covariates. In the model for IBD as response, only HLA-B27 (reference: negative) was entered as factor, and age (years) and axSpA disease duration (years) as covariates. For each EAM, the final models’ type was Poisson log-linear, the maximum iterations were 100 and maximum step-halving was 5. The convergence criteria defined as a change in parameter estimate of 1e-006 or more.

To examine the associations between EAMs and the choice of first TNFi, logistic regression models were used. In univariable analyses, separate models were constructed with etanercept versus monoclonal TNFis as dependent variable, and pretreatment diagnosis of
AAU, psoriasis and IBD (as Crohn’s disease only, ulcerative colitis only and combined). Other demographic and lifestyle factors included in the models were age, gender, axSpA disease duration, BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) score, BASFI (Bath Ankylosing Spondylitis Functional Index) score, HLA-B27 status, smoking status, education and BMI. Factors with significant associations (p<0.05) in univariable models were entered into the multivariable model, again with choice of TNFi (etanercept vs monoclonal TNFis) as dependent variable. Pretreatment diagnosis of AAU, IBD, education status, BASDAI and BASFI were included in the final model. The entered method was chosen for the final multivariable analyses to keep all variable in the model. Magnitude of associations were presented as ORs and 95% CI.

RESULTS
Baseline data for 2419 participants were available for the current analysis. Approximately a third of the cohort (927; 32%) had one or more EAM of interest present prior to receiving biological therapy; of these 780 (84.1%) had only one EAM, 142 (15.3%) had two EAMs and 5 (0.5%) participants had all three EAMs. The frequency of AAU, psoriasis and IBD at the baseline visit were 23.5% (568), 10.9% (264) and 10.2% (247), respectively. The baseline demographic, lifestyle factors and HLA-B27 status of the whole cohort and those with EAMs are shown in table 1.

Associations with AAU
AAU was the most common EAM reported in 568 (23.5%) of participants (table 1). In the univariable analysis, significant positive associations in the AAU cohort included older age (IRR 1.01, 95% CI 1.01 to 1.021 per year), longer disease duration (IRR 1.02, 95% CI 1.01 to 1.02), HLA-B27 (IRR 1.92, 95% CI 1.42 to 2.61) and university education (1.30, 95% CI 1.021 per year so may still have a cumulative effect over time.

Table 1 Characteristics of entire cohort and subgroups with extra-articular manifestations

|                                | Entire cohort (n=2419) | With AAU (n=568, 23.5%) | With psoriasis (n=264, 10.9%) | With IBD (n=247, 10.2%) |
|--------------------------------|------------------------|--------------------------|-------------------------------|-------------------------|
| Gender (male)                  | 68.4%                  | 66.7%                    | 67.4%                         | 65.2%                   |
| Age (years), median (IQR)      | 47.0 (36.0–59.0)       | 51.0 (41.0–61.0)         | 51.5 (38–62)                  | 52.0 (40.0–63.0)        |
| AxSpA disease duration (years), median (IQR) | 16.0 (7.0–30.0)   | 22.0 (11.0–34.0)         | 17.5 (7.0–32.0)               | 20.0 (8.0–35.0)         |
| BMI (kg/m²), median (IQR)      | 26.8 (23.9–30.7)       | 27.3 (24.0–31.0)         | 27.7 (24.4–31.4)              | 27.1 (24.0–30.8)        |
| HLA-B27 positive               | 80.1%                  | 88.7%                    | 86.7%                         | 71.4%                   |
| University degree              | 27.8%                  | 33.5%                    | 27.2%                         | 24.8%                   |
| Ever-smoker                    | 56.2%                  | 50.1%                    | 62.7%                         | 59.7%                   |
| Ever-drinking alcohol          | 93.0%                  | 94.2%                    | 94.0%                         | 92.1%                   |

AAU, acute anterior uveitis; axSpA, axial spondyloarthritis; BMI, body mass index; HLA, human leukocyte antigen; IBD, inflammatory bowel disease.

Associations with psoriasis
Psoriasis was reported in 264 (10.9%). In univariable analysis, significant positive associations with psoriasis were seen for older age (IRR 1.01, 95% CI 1.01 to 1.02), BMI (IRR 1.03, 95% CI 1.01 to 1.05) and ever-smoking (IRR 1.30, 95% CI 1.00 to 1.70), while the participants with axSpA and psoriasis were less likely to be HLA-B27 positive (IRR 0.50, 95% CI 0.36 to 0.64). Ever-drinking alcohol or having a university degree were not significantly different in the psoriasis group compared to the entire cohort. In the multivariable analysis (table 2), only HLA-B27 status remained as independent predictor of psoriasis (IRR 0.54, 95% CI 0.37 to 0.79). The other parameters, including age and BMI, did not demonstrate a statistically significant association with a diagnosis of psoriasis in this axSpA cohort.
Associations with IBD

There were 247 (10.2%) patients with a diagnosis of IBD (table 1). In the univariable analysis, positive associations with IBD were older age (IRR 1.02, 95% CI 1.01 to 1.03) and longer axSpA disease duration (IRR 1.01, 95% CI 1.00 to 1.02). In contrast, HLA-B27 was significantly lower in the IBD group (IRR 0.65, 95% CI 0.43 to 0.89). There were no significant associations in this cohort between a diagnosis of IBD and ever-smoking, ever-drinking, BMI or education level.

Similar to the findings in participants with psoriasis, multivariable analysis identified only HLA-B27 status as an independent negative predictor of a diagnosis of IBD with an IRR of 0.63 (95% CI 0.43 to 0.91). Other parameters including age and axSpA disease duration did not demonstrate a statistically significant association with IBD (table 2).

EAMs and choice of biologic

A total of 947 (39.1%) participants received their first biologic during the course of the observation period. The TNFi biologics were adalimumab (n=598, 63.1%; all Humira), etanercept (n=266, 28.1%; consisted of 240 Enbrel and 26 biosimilar Benepali), certolizumab (n=73, 7.7%) and golimumab (n=9, 1.0%). One participant (0.1%) treated with the interleukin (IL)-17A inhibitor, secukinumab, was excluded from this analysis. Overall, the presence of EAMs did not influence the likelihood of receiving treatment with TNFi, with 66% of participants with an EAM receiving TNFi compared with 66.4% without an EAM (p=0.836).

Treatment and choice of biologic in the BSRBR-AS cohort was at the discretion of the usual treating clinical physician and unrelated to participation in the study. In order to determine which demographic factors and disease measurements were associated with selection of the soluble fusion protein TNFi, etanercept, compared to the monoclonal antibody TNFis (adalimumab, certolizumab or golimumab in this cohort), separate logistic regression models were developed. Univariable analysis revealed that baseline BASDAI score (OR 1.15, 95% CI 1.06 to 1.24) and BASFI score (OR 1.11, 95% CI 1.04 to 1.18) were significantly associated with the choice of etanercept over monoclonal TNFi. Conversely, having higher education (university education and above) was associated with less use of etanercept over monoclonal TNFi (OR 0.73, 95% CI 0.54 to 0.99). None of other demographic or lifestyle variables, including age, gender, disease duration, HLA-B27, smoking and BMI, were associated with the choice of TNFi.

Considering EAMs in the univariable models, ever diagnosis of AAU (as binary yes: no) and number of AAU episodes in the last 12 months were both significantly associated with less use of etanercept compared to monoclonal TNFi (OR 0.29, 95% CI 0.19 to 0.46 and OR 0.48, 95% CI 0.30 to 0.77, respectively)). Also, patients with ever diagnosis of IBD in any form (all IBD, Crohn’s disease alone and ulcerative colitis alone) were less likely to

Table 2  Factors and covariates associated with a diagnosis of specific EAM in patients with axSpA (multivariable models)

| Parameter                      | B       | SE       | P value | Incidence rate ratio (IRR) | 95% CI for IRR |
|--------------------------------|---------|----------|---------|---------------------------|----------------|
| A. Diagnosis of AUU            |         |          |         |                           |                |
| (Intercept)                    | -2.370  | 0.2788   | <0.001  | 0.093                     | 0.054–0.161    |
| HLA-B27 positive (vs negative) | 0.669   | 0.1710   | <0.001  | 1.953                     | 1.396–2.730    |
| University degree (vs lower)   | 0.165   | 0.1507   | 0.273   | 1.179                     | 0.878–1.585    |
| Ever-smoking (vs never)        | -0.349  | 0.1322   | 0.008   | 0.706                     | 0.545–0.915    |
| Age (years)                    | 0.009   | 0.0053   | 0.093   | 1.009                     | 0.999–1.019    |
| axSpA disease duration (years) | 0.005   | 0.0050   | 0.305   | 1.005                     | 0.995–1.015    |
| B. Diagnosis of Psoriasis      |         |          |         |                           |                |
| (Intercept)                    | -3.069  | 0.592    | 0.000   | 0.046                     | 0.015–0.148    |
| HLA-B27 positive (vs negative) | -0.621  | 0.197    | 0.002   | 0.538                     | 0.365–0.791    |
| University degree (vs lower)   | 0.326   | 0.283    | 0.248   | 1.386                     | 0.796–2.412    |
| Ever-smoking (vs never)        | 0.256   | 0.228    | 0.262   | 1.292                     | 0.826–2.020    |
| Age (years)                    | 0.009   | 0.007    | 0.173   | 1.009                     | 0.996–1.022    |
| BMI (kg/m²)                    | 0.022   | 0.016    | 0.155   | 1.023                     | 0.992–1.05     |
| C. Diagnosis of IBD            |         |          |         |                           |                |
| (Intercept)                    | -2.698  | 0.3617   | <0.001  | 0.067                     | 0.033–0.137    |
| HLA-B27 positive (vs negative) | -0.466  | 0.1894   | 0.014   | 0.627                     | 0.433–0.909    |
| Age (years)                    | 0.012   | 0.0079   | 0.128   | 1.012                     | 0.997–1.028    |
| axSpA disease duration (years) | 0.003   | 0.0078   | 0.671   | 1.003                     | 0.988–1.019    |

AAU, acute anterior uveitis; axSpA, axial spondyloarthritis; BMI, body mass index; EAM, extra-articular manifestation; HLA, human leukocyte antigen; IBD, inflammatory bowel disease.
receive etanercept over monoclonal TNFi in univariable models (OR 0.35, 95% CI 0.20 to 0.62). In contrast, ever diagnosis of psoriasis was not associated with choice of any particular TNFi (OR 0.74, 95% CI 0.47 to 1.16) (table 3).

In multivariable analysis (table 4), both ever diagnosis of AAU (OR 0.15, 95% CI 0.08 to 0.29) and ever diagnosis of IBD (OR 0.30, 95% CI 0.16 to 0.56) remained significantly associated with less use of etanercept compared to monoclonal TNFis. Among other factors, only BASDAI score had a significant association with the preference of etanercept over monoclonal TNFi (OR 1.16, 95% CI 1.03 to 1.30).

**DISCUSSION**

In this large real-world cohort of patients with axSpA, EAMs are common, with approximately a third of participants reporting at least one EAM. The occurrence of EAMs in this cohort is approximately similar to previous published reports in similar populations.12–14 Interestingly, among patients who had EAMs, most (84%) of the participants only had a single EAM, suggesting that while there may be shared pathogenic processes between EAMs and axSpA, there are also likely to be unrelated pathogenic mechanisms. This is consistent with the existing and emerging pathogenetic and treatment response data for these conditions.15 16

The presence of AAU in this axSpA cohort was significantly associated with HLA-B27 status. This is consistent with previous reports7 17 and offers a potential strategy for targeted identification of people with AAU in ophthalmology clinics who may have underlying axSpA.18–20 Interestingly, participants with IBD and psoriasis had lower rates of HLA-B27 positivity than the overall cohort and both had negative associations with HLA-B27 status, consistent with results from a recent study by Varkas et al.21 This may indicate that people with psoriasis or IBD and back pain are more likely to be diagnosed with axSpA, regardless of their HLA-B27 status. Interestingly, a positive HLA-B27 (plus at least two other SpA features, which could include psoriasis or IBD) is required to fulfil the clinical arm of the ASAS classification criteria for axSpA10; this may suggest that these participants are more likely to fulfil the imaging arm (HLA-B27 not required). An alternative explanation could be that clinicians rely more on diagnostic likelihood and clinical acumen rather than rigorously adhering to classification criteria, which would be appropriate as classification criteria are not intended for diagnostic use in clinical practice.22 23 Finally, it is also possible that axSpA is under-diagnosed in patients with dominant IBD or psoriasis, particularly those who are HLA-B27 positive.24–27

The current study indicated that smoking is associated with lower occurrence of AAU but not associated with psoriasis or IBD. The inverse association between AAU

---

**Table 3** Summary of factors associated with choice of etanercept over monoclonal antibody TNFis in patients with axSpA (summary of separate univariable models)

| Variable                        | Wald  | P value | OR   | 95% CI for OR |
|---------------------------------|-------|---------|------|---------------|
| Gender (male vs female)         | 3.561 | 0.059   | 1.351| 0.988–1.847   |
| Age (years)                     | 0.842 | 0.359   | 0.995| 0.984–1.006   |
| Disease duration (years)        | 2.062 | 0.151   | 0.992| 0.980–1.003   |
| BASDAI score                    | 12.226| <0.001  | 1.146| 1.062–1.237   |
| BASFI score                     | 10.393| 0.001   | 1.107| 1.041–1.178   |
| HLA-B27 positivity              | 0.033 | 0.856   | 1.038| 0.692–1.557   |
| Smoking (current vs none)       | 1.525 | 0.217   | 1.268| 0.870–1.848   |
| Smoking (ex-smoking vs none)    | 0.084 | 0.772   | 1.054| 0.736–1.510   |
| Education (ordinal)             | 3.543 | 0.060   | 0.893| 0.793–1.005   |
| Education (university degree vs lower) | 4.084 | 0.043 | 0.730 | 0.539–0.991 |
| BMI (kg/m²)                     | 0.365 | 0.546   | 0.956| 0.826–1.106   |
| AAU (any)                       | 27.943| <0.001  | 0.294| 0.187–0.463   |
| AAU episodes in last 12 months  | 9.336 | 0.002   | 0.484| 0.304–0.771   |
| IBD (Crohn’s disease or ulcerative colitis) | 13.081| <0.001 | 0.354| 0.201–0.621   |
| Crohn’s disease                 | 9.457 | 0.002   | 0.044| 0.006–0.323   |
| Ulcerative colitis              | 7.456 | 0.006   | 0.192| 0.056–0.628   |
| Psoriasis                       | 1.707 | 0.191   | 0.738| 0.468–1.164   |

AAU, acute anterior uveitis; axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; IBD, inflammatory bowel disease; TNFi, tumour necrosis factor-inhibitor.

**Table 4** Summary of factors associated with choice of etanercept over monoclonal TNFis in patients with axSpA (summary of multivariable model)

| Variable                        | Wald  | P value | OR   | 95% CI for OR |
|---------------------------------|-------|---------|------|---------------|
| BASDAI score                    | 5.941 | 0.015   | 1.158| 1.029–1.304   |
| BASFI score                     | 0.315 | 0.577   | 1.028| 0.932–1.135   |
| Education (university degree vs lower) | 1.098 | 0.295 | 0.836 | 0.597–1.169 |
| AAU (any)                       | 35.266| <0.001  | 0.154| 0.083–0.286   |
| IBD (Crohn’s disease or ulcerative colitis) | 13.853| <0.001 | 0.296| 0.156–0.562   |

AAU, acute anterior uveitis; axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; IBD, inflammatory bowel disease; TNFi, tumour necrosis factor-inhibitor.
and smoking was evident in both unadjusted and adjusted models. However, smoking is considered an established risk factor for AAU and its negative association with AAU in this study should be interpreted with caution. First, there are differences between studies regarding comparison groups; all participants of the current study had confirmed axSpA, in contrast to studies reporting the associations with different background diseases or even in the general population. Furthermore, while a similar inverse association between smoking and AAU was reported in a recent study using the same registry data, subsequent analysis showed that smoking does not protect patients with axSpA from uveitis attacks. Other studies have also demonstrated this negative association between smoking and uveitis: Jones et al, in a study of around 1000 patients from Scotland, found that ex-smokers were more than twice as likely to have a history of uveitis compared to current smokers. Further investigation using different populations and methodology designed specifically to examine the relationship between AAU and smoking in patients with axSpA is required.

The presence of EAMs in general did not increase the likelihood of participants being started on a biologic in this cohort. This presumably reflects the focus on axSpA disease activity threshold scores in the axSpA treatment recommendations, such that the decision to prescribe biologics in axSpA is based largely on axSpA disease activity assessment by the rheumatology team, rather than the overall disease burden. IBD and psoriasis often require biological therapy in their own right (prescribed by gastroenterologists or dermatologists), but these patients are unlikely to be captured in this cohort which only recruited participants from rheumatology clinics, so the cohort may have missed those with the most severe IBD, psoriasis or AAU. As EAMs contribute to the disease burden in axSpA, it could be argued that a composite axSpA disease burden score incorporating EAMs, and functional measures, might be more representative of the true axSpA disease burden than the current disease activity scores (BASDAI and ASDAS), which are dominated by subjective pain and fatigue scores. This approach may be worthy of further study and help address the value of combined clinics with other specialties. Although we believe that rheumatologists usually take the full burden of disease into consideration, in many countries, patient-reported outcomes are used as a reimbursement criterion.

The presence of EAMs, specifically IBD and AAU, did however influence the choice of TNFi. It is clear that rheumatologists are taking the lack of evidence (or even paradox effect) for etanercept in IBD, and to a lesser extent also AAU into consideration when choosing a specific TNFi for patients with axSpA. The presence of psoriasis did not appear to influence the choice of TNFi in this cohort, which was largely recruited prior to the introduction and wide-spread use of IL-17A inhibitors. EAMs are likely to have a major impact on the choice of TNFi versus IL-17A inhibitors in axSpA as there remains concern about the latter exacerbating IBD. In contrast, IL-17A inhibitors have been shown in head-to-head studies to have greater efficacy in psoriasis. It should be noted that to-date no head-to-head studies of biologics have been reported in axSpA, so data from observational studies will be required to help address these questions. It is unfortunate that, due to the funding of the BSRBR-AS, for the majority of the data collection period only certain TNFi agents were eligible for inclusion. For example, the study therefore has no participants commencing infliximab as first-choice TNFi. However, in the current analysis, all monoclonal antibodies were analysed as a group, and we believe it is unlikely that the additional of patients on infliximab (had that data been available) would have altered the conclusions in the comparison between monoclonal antibodies versus the soluble fusion protein etanercept. Beyond the impact of EAMs on choice of biologic in axSpA assessed in this study, longitudinal real-world studies will be required to assess the impact of EAMs on TNFi retention, which will help inform treatment decisions and recommendations for the use of biologics in axSpA. Lindstrom et al reported that AAU and psoriasis but not IBD affect retention of first TNFi in a Swedish cohort of patients with AS; however, more data are needed.

This ‘real-world’ cohort provides valuable information on the occurrence of EAMs in axSpA and their influence on TNFi prescribing patterns. The main strength of the study is the large sample size and the fact that patients have been recruited from 83 specialist and non-specialist centres throughout the UK. To our knowledge, this is the first study designed to address this subject. It is reassuring to note that clinicians are prescribing in line with licenced and international recommendations. Future analysis will determine whether EAMs influence TNF efficacy and survival and whether or not individual TNFi protect patients from incident or flares of existing EAMs.

Author affiliations
1Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UK
2Epidemiology Group, University of Aberdeen, Aberdeen, UK
3Rheumatology Department, Norfolk and Norwich University Hospital, Norwich, UK

Acknowledgements We are grateful to the staff of the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis register and to the recruiting staff at the clinical centres, details of which are available at https://www.abdn.ac.uk/iahs/research/epidemiology/bsrbras-1438.php

Twitter @tareq_senoj.

Contributors Study concept and design: MHD, SS, KG. Analysis and interpretation of data: all authors. Drafting the manuscript: MHD, SS, KG. Critical revision of the manuscript for important intellectual content: all authors.

Funding This work was supported by the British Society for Rheumatology (BSR) who have funded the BSRBR-AS. The BSR received funding for this from Pfizer, AbbVie and UCB. These companies receive advance copies of manuscripts for comments but have no input into the topics for analysis in the register nor the work involved in undertaking analysis. Original analysis of data was supported by the Versus Arthritis/Medical Research Council Centre for Musculoskeletal Health and Work (grant number 20665). The current analyses were funded by the British Society of Spondyloarthritis (BritSpA).
Competing interests: GTJ reports grants from AbbVie, Pfizer and UCB during the conduct of the study; grants from Amgen and GoxoSmithKline, outside the submitted work. SS has received research grants, speaker or consultancy fees from AbbVie, Amgen (previously Celgene), BMS, Boehringer-Ingelheim, GoxoSmithKline, Janssen, Novartis, Pfizer and UCB. KG has received research grants, speaker or consultancy fees from AbbVie, Celgene, Biogen, MSD, Novartis, Pfizer and UCB Pharma. Other authors have no relevant interests to declare.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs
Mohammad H Derakhshan http://orcid.org/0000-0002-7863-9176
Linda Dean http://orcid.org/0000-0001-7667-5352

REFERENCES
1 de Winter JJ, van Mens LJ, van der Heijde D, et al. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. Arthritis Res Ther 2016;18:196.
2 Spondyloarthritis in over 16s: diagnosis and management. NICE Guideline, No. 65. National Institute for Health and Care Excellence (UK), London: National Institute for Health and Care Excellence (UK), 2017 Feb.
3 Gao X, Wendling D, Dotteman MF, et al. Clinical and economic burden of extra-axial manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. J Med Econ 2012;15:1054–63.
4 van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76:978–91.
5 Deodhar A. Axial spondyloarthritis criteria and modified NY criteria: issues and controversies. Clin Rheumatol 2014;33:741–7.
6 Lee JT, Yates WB, Rogers S, et al. Adalimumab for the treatment of refractory active and intractable non-infectious uveitis. Br J Ophthalmol 2018;102:1672–8.
7 Frantz C, Portier A, Etcheto A, et al. Acute anterior uveitis in spondyloarthritis: a monocentric study of 301 patients. Clin Exp Rheumatol 2019;37:26–31.
8 Sharma SM, Jackson D. Uveitis and spondyloarthropathies. Best Pract Res Clin Rheumatol 2017;31:846–62.
9 Fabiani C, Vitale A, Lopalco G, et al. Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art. Clin Rheumatol 2016;35:2631–8.
10 Rudwaleit M1, van der Heijde D, Landewé R, et al. The development of assessment of spondyloarthritis International Society Classification Criteria for Axial Spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777–83.
11 Macfarlane GJ, Barnish MS, Jones EA, et al. The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment. BMC Musculoskelet Disord 2015;16:347.
12 Stolwijk C, van Tongeren A, Castillo-Ortiz JD, et al. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis 2015;74:65–73.
13 Dougdas M, Etcheto A, Molto A, et al. Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis. Eur J Clin Investig 2015;45:328–38.
14 Essers I, Ramiro S, Stolwijk C, et al. Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. Rheumatology (Oxford) 2019;58:725–31.
15 Reveille JD. Genetics of spondyloarthritis: beyond the MHC. Nat Rev Rheumatol 2012;8:296–304.
16 Siebert S, Millar NL, McIntnes IB. Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? Ann Rheum Dis 2019;78:1015–18.
17 Georgovyan O, Riad M, Sarran RD, et al. Anterior uveitis in patients with spondyloarthropathies in a single US academic center: a retrospective study. Rheumatol Int 2019;39:1607–14.
18 Wallis D, Inman RD. Recognition of preclinical and early disease in axial spondyloarthritis. Rheum Dis Clin North Am 2014;40:685–97.
19 Haroon M, O’Rourke M, Ramsamy P, et al. A novel evidence-based detection of undiagnosed spondyloarthritis in patients presenting with acute anterior uveitis: the DUET (Dublin Uveitis Evaluation Tool). Ann Rheum Dis 2015;74:1960–6.
20 Sykes MP, Hamilton L, Jones C, et al. Prevalence of axial spondyloarthritis in patients with acute anterior uvea: a cross-sectional study utilising MRI. RMD Open 2018;4:e000553.
21 Varkas G, Vastesaeger N, Cypers H, et al. Association of inflammatory bowel disease and anterior uveitis, but not posterior uveitis, with disease duration in patients with axial spondyloarthritis: results from two Belgian nationwide axial spondyloarthritis cohorts. Arthritis Rheumatol 2018;70:1588–96.
22 Aggarwal R, Ringold S, Khanna D, et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res (Hoboken) 2015;67:891–7.
23 Dubreuil M, Deodhar AA. Axial spondyloarthritis classification criteria: the debate continues. Curr Opin Rheumatol 2017;29:217–22.
24 Vinge O, Dale K, Møller S, et al. Radiographic changes, HLA B27 and back pain in patients with psoriasis or acute anterior uveitis. Scand J Rheumatol 1983;12:219–24.
25 de Vlam K, Mielants H, Cuvelier C, et al. Spondyloarthritis is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol 2000;27:2860–5.
26 Jodon DR, Sengupta R, Nightingale A, et al. Axial disease in psoriatic arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Ann Rheum Dis 2017;76:701–7.
27 Kelly OB, Li N, Smith M, et al. Clinical associations of subclinical sacroiliitis in inflammatory bowel disease. Inflamm Bowel Dis 2019;25:1066–71.
28 Yuen BG, Tham VM, Browne EN, et al. Association between smoking and uveitis: results from the Pacific Ocular Inflammation Study. Ophthalmology 2017;124:677–81.
29 Lin P, Loh AR, Margolis TP, et al. Cigarette smoking as a risk factor for uveitis. Ophthalmology 2010;117:585–90.
30 Zhao S, Jones GT, Macfarlane GJ, et al. Associations between smoking and extra-axial manifestations and disease severity in axial spondyloarthritis: results from the BSR Biologics Register for Ankylosing Spondylitis (BSRBR-AS). Rheumatology (Oxford) 2019;58:811–9.
31 Zhao SS, Macfarlane GJ, Jones GT, et al. Smoking does not protect patients with axial spondyloarthritis from attacks of uveitis. Ann Rheum Dis 2019;78:1287–8.
32 Jones GT, Ratz T, Dean LE, et al. Disease severity in never smokers, ex-smokers, and current smokers with axial spondyloarthritis: results from the Scotland Registry for Ankylosing Spondylitis. Arthritis Care Res (Hoboken) 2017;69:1407–13.
33 Zhao SS, Yoshida K, Jones GT, et al. Impact of smoking in response to tumor necrosis factor inhibitors in axial spondyloarthritis: methodologic considerations for longitudinal observational studies. Arthritis Care Res (Hoboken) 2020;72:591–9.
34 Korzenik J, Larsen MD, Nielsen J, et al. Increased risk of developing Crohn’s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. Aliment Pharmacol Ther 2019;50:2894–9.
35 Hubeer W, Sands BE, Lewitsky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012;61:1693–700.
36 Targan SR, Feagan B, Vermeire S, et al. An randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn’s disease. Am J Gastroenterol 2016;111:1599–607.
37 Langley RG, Eleswi BE, Lebowh M, et al. Secukinumab in plaque psoriasis: results of two phase 3 trials. N Engl J Med 2014;371:320–9.
38 Griffiths CE, Reich K, Lebowih M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015;386:541–51.
39 Lindström U, Olofsen T, Wedrén S, et al. Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study. RMD Open 2018;4:e000762.